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Abstract
Dopamine, through D2 receptor (D2R), is the major regulator of lactotrope function in the anterior pituitary gland. Both D2R
isoforms, long (D2L) and short (D2S), are expressed in lactotropes. Although both isoforms can transduce dopamine signal,
they differ in the mechanism that leads to cell response. The administration of D2R agonists, such as cabergoline, is the
main pharmacological treatment for prolactinomas, but resistance to these drugs exists, which has been associated with
alterations in D2R expression. We previously reported that dopamine and cabergoline induce apoptosis of lactotropes in
primary culture in an estrogen-dependent manner. In this study we used an in vivo model to confirm the permissive action
of estradiol in the apoptosis of anterior pituitary cells induced by D2R agonists. Administration of cabergoline to female rats
induced apoptosis, measured by Annexin-V staining, in anterior pituitary gland from estradiol-treated rats but not from
ovariectomized rats. To evaluate the participation of D2R isoforms in the apoptosis induced by dopamine we used
lactotrope-derived PR1 cells stably transfected with expression vectors encoding D2L or D2S receptors. In the presence of
estradiol, dopamine induced apoptosis, determined by ELISA and TUNEL assay, only in PR1-D2S cells. To study the role of
p38 MAPK in apoptosis induced by D2R activation, anterior pituitary cells from primary culture or PR1-D2S were incubated
with an inhibitor of the p38 MAPK pathway (SB203850). SB203580 blocked the apoptotic effect of D2R activation in
lactotropes from primary cultures and PR1-D2S cells. Dopamine also induced p38 MAPK phosphorylation, determined by
western blot, in PR1-D2S cells and estradiol enhanced this effect. These data suggest that, in the presence of estradiol, D2R
agonists induce apoptosis of lactotropes by their interaction with D2S receptors and that p38 MAPK is involved in this
process.
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Introduction
Dopamine (DA) is the predominant catecholaminergic neuro-
transmitter in the mammalian brain and is involved in a variety of
functions such as locomotion, reinforcement, food intake, emotion
and neuroendocrine secretion. In the anterior pituitary gland, DA
inhibits prolactin (PRL) synthesis and release, as well as lactotrope
proliferation [1]. In addition to these well established actions, we
previously reported that DA induces apoptosis of lactotropes from
female rats in an estrogen-dependent manner [2]. These pituitary
actions are exerted through the D2 receptor (D2R), a member of
the G protein-coupled receptor superfamily [3].
D2R exists as two alternatively spliced isoforms, long (D2L) and
short (D2S). D2L differs from D2S by the presence of additional
29 amino acid residues within the third intracellular loop. D2L
and D2S can couple to different G inhibitory proteins [4,5] and,
although both isoforms can transduce the intracellular signal
correctly [4], it has been reported that D2S is more efficient for
inhibiting adenylyl cyclase than D2L [6]. Both isoforms can be
expressed in the same cell, but D2L is the main isoform present in
the anterior pituitary, and estradiol (E2) was shown to increase the
D2L/D2S ratio [7–9].
Cabergoline (CAB), a D2R agonist, is the most effective
compound for pharmacological treatment of prolactinomas [10],
strongly reducing PRL secretion and lactotrope proliferation
[11,12]. Although DA agonists have been proven to be successful
in normalizing serum PRL levels, a subset of patients with
prolactinomas does not respond to CAB, suggesting that D2R
expression is altered. In fact, prolactinomas resistant to D2R agonist
treatment have been shown to express less D2R mRNA than
responsive tumors [13]. Moreover, some studies suggest that
alterations in the proportion of D2L and D2S isoform expression
could be involved in D2R agonist resistance [10,14,15]. In addition,
estrogens sensitize anterior pituitary cells to different proapoptotic
stimuli [16,17], and we have observed that CAB induces apoptosis
of lactotropes only when cells are cultured in the presence of E2 [2],
making it plausible that the hormonal milieu could affect the action
of D2R agonists in patients with prolactinomas.
D2R is coupled to distinct intracellular pathways including
different MAPKs [18]. DA-induced apoptosis of neuroblastoma
cells [19] and pituitary-derived GH3 cell line [20] involves p38
MAPK activation. The abnormal transduction of D2R signaling
could also explain the failure of D2R agonist treatment in
resistant prolactinomas [10].
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In the present work, we studied the role of D2R isoforms, D2L
and D2S in the apoptosis of lactotropes induced by DA. We also
investigated the participation of p38 MAPK in this action. We
confirm the influence of E2 in the proapoptotic action of CAB on
anterior pituitary cells in an in vivo model.
Also, we show that DA induces apoptosis of lactotropes through
D2S receptor activation in an E2-dependent manner and that p38
MAPK is involved in this action.
Methods
Ethics Statement
All procedures complied with the Ethical Committee of the
School of Medicine, University of Buenos Aires and the NIH
Guide for the Care and Use of Laboratory Animals.
Drugs
All drugs, media and supplements were obtained from
Invitrogen (Carlsbad, CA, USA), except Dulbecco’s modified
Eagle’s medium (DMEM), bovine serum albumin (BSA), 17b-
estradiol (E2), DA, normal horse serum and protease inhibitor
cocktail (Sigma, St. Louis, MO, USA), fetal bovine serum (GBO,
Buenos Aires, Argentina), SB203580 (Stressgen, PA, EEUU),
gentamicin (Promega, Madison,WI), Vectashield (Vector Labora-
tories, Inc., Burlingame, CA, USA), all terminal deoxynucleotidyl
transferase-mediated deoxyuridine triphosphate nick end-labeling
(TUNEL) reagents (Roche Molecular Biochemicals, Mannheim,
Germany), Cell Death Detection (ELISAPlus) (Roche Molecular
Biochemicals, Mannheim, Germany), guinea pig rat prolactin
antiserum (Dr. A. Parlow, National Hormone and Pituitary
Program, Torrance, CA, USA), anti-guinea pig rhodamine-
conjugated secondary antibody (Chemicon International, Teme-
cula, CA, USA), fluorescein isothiocyanate (FITC) Annexin-V (BD
Pharmingen, San Jose, CA, USA), anti-p38 MAPK and anti-
phospho-p38 MAPK antibodies (Cell Signaling Technology, CA,
USA) and cabergoline (kindly donated by Holliday-Scott, Buenos
Aires, Argentina).
Animals
Adult female Wistar rats were kept in controlled conditions of
light (12 hour light-dark cycles) and temperature (20–25uC).
Animals were fed standard lab chow and water ad libitum. The
rats were ovariectomized (OVX) under ketamine (75 mg/kg, i.p.)
and xylazine (10 mg/kg, i.p.) anesthesia. For primary cultures, the
rats were euthanized by decapitation 15 days after ovariectomy
and anterior pituitary glands were removed. For in vivo
experiments, the rats were s.c. implanted in the skin of the back
with silicone capsules containing 1 mg of 17b-estradiol (E2) or
empty capsules (OVX) at the time of ovariectomy. The capsules
(length 20 mm, outer diameter 2 mm) were prepared in the
laboratory and were filled with 50 ml of E2 solution (20 mg/ml)
diluted in ethanol. When ethanol was evaporated the capsules
were sealed with a silicone adhesive. These capsules induce plasma
levels of E2 similar to those of rats at proestrus [21]. After 15 days
of ovariectomy, the rats were injected with cabergoline (CAB,
1 mg/kg, i.p.) or 0.9% NaCl (CONTROL). After 16 h, the rats
were euthanized, anterior pituitary glands obtained and cells
dispersed to analyze apoptosis by Annexin-V staining.
Primary culture of anterior pituitary cells
A pool of anterior pituitary cells from 5–8 OVX rats was used
for each primary culture. Anterior pituitary glands were washed
several times with DMEM supplemented with 10 ml/ml
MEM amino acids, 2 mM glutamine, 5.6 mg/ml amphotericin B,
25 mg/ml gentamicin (DMEM-S) and 3 mg/ml BSA. Then the
glands were cut into small fragments and dispersed enzymatically
by successive incubations in DMEM-S with BSA, containing
0.75% trypsin, deoxyribonuclease type I (DNase; 45 U/ml) and
10% fetal calf serum previously treated with 0.025% dextran-
0.25% charcoal (FCS) to remove steroids. The cells were then
washed with Krebs-Ringer bicarbonate buffer free of Ca2+ and
Mg2+ (KRBCMF), pH 7.4. Finally, the cells were dispersed in
KRBCMF by extrusion through a Pasteur pipette. Dispersed cells
were washed twice and resuspended in DMEM-S with 10% FCS.
Cell dispersion yielded about 3–3.56106 cells/gland. Cell viability
as assessed by trypan blue exclusion was over 90%. The cells were
seeded onto coverslides in 24-well tissue culture plates (16105
cells/ml/well) and cultured in DMEM-S with 10% FCS for 24 h.
Then the cells were cultured in fresh medium containing 17b-
estradiol (E2, 1 nM) for 24 h and in the same media without
serum for a further 24 h. After this period, cells were incubated in
the same media containing different drugs according to each
experiment.
Cell lines
The PR1 cell line was derived from a pituitary tumor of a
Fischer-344 ovariectomized rat treated with E2 for 3 months [22].
These cells do not express D2Rs [23] and secrete PRL [22]. Stably
transfected PR1 cells with an expression vector containing cDNA
encoding D2L (PR1-D2L), D2S (PR1-D2S) receptors or an empty
vector (PR1-V) [23] were maintained in a 1:1 mixture of
Dulbecco’s modified Eagle’s medium and Ham’s F-12 medium
(DMEM/F-12; Sigma) containing 10% FBS previously treated
with 0.025% dextran-0.25% charcoal and 800 mg/ml gentamicin.
The cells were seeded onto coverslides in 24-well culture plates
(16105 cells/ml/well) for the TUNEL method, in 24-well culture
plates (56105 cell/ml/well) for ELISA or in 6-well plates (16106
cells/ml/well) for protein extraction. Then, the cells were
maintained for 24 h in DMEM/F-12 supplemented with human
transferrine (100 mM), insulin (5 mM), putrescine (1 mM) and
sodium selenite (30 nM) without serum (DMEM/F-12-SS).
Finally, the cells were cultured with vehicle (VEH, ethanol,
1 ml/l) or E2 (1 nM) in DMEM/F-12-SS for 48 h and incubated
in the same media containing different drugs according to each
experiment.
Detection of Apoptosis by FITC Annexin-V Staining
Anterior pituitary glands from in vivo experiments were
dispersed with trypsin/DNase as previously described [2]. Then
the cells were washed in cold PBS and resuspended in binding
buffer (10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM
CaCl2). The cells were incubated with 5 ml FITC Annexin-V and
10 ml propidium iodide (PI, 50 mg/ml) for 15 min in darkness.
Cells were immediately analyzed by flow cytometry (Becton-
Dickinson FACScalibur) and data analyzed by WinMDI98
software. Annexin-V-positive/PI-negative cells were considered
early apoptotic cells, whereas Annexin-V-negative/PI-positive
cells were considered necrotic cells. Double-positive (Annexin-V-
positive/PI-positive) cells were considered to be in a late stage of
apoptosis.
Detection of Apoptosis by Cell Death Detection
(ELISAPLUS)
The apoptotic response of PR1 cells was measured by Cell
Death Detection (ELISAPlus). This kit is used for relative
quantification of histone-complexed DNA fragments (mono- and
oligonucleosomes) induced by apoptosis. After treatment, cells
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were lysed to obtain the nucleosomes and processed according to
the manufacturer’s protocol. Optic density (OD) was measured in
a spectrophotometer at 405 nm.
Detection of Apoptosis by TUNEL assay
After the culture period, the cells were fixed with 4%
paraformaldehyde for 10 min and permeabilized by microwave
irradiation. DNA strand breaks were labeled with digoxigenin-
deoxyuridine triphosphate using terminal deoxynucleotidyl trans-
ferase (0.18 U/ml) according to the manufacturer’s protocol. After
incubation with 10% horse serum, slides were incubated for 1 h
with antidigoxigenin-fluorescein antibody (aDIG, 1:10) to detect
incorporation of nucleotides into the 3-OH end of damaged
DNA. Slides were mounted with Vectashield (Vector Laborato-
ries, Inc., Burlingame, CA, USA) containing 4,6 diamidino-2-
phenylindoledihydrocloride (DAPI) for DNA staining and
visualized in a fluorescence light microscope (Axiophot; Carl
Zeiss Jena, Germany). In primary culture of anterior pituitary
cells, lactotropes were identified by immunofluorescence. After
incubation with 10% serum in PBS, the cells were incubated for
1 h with guinea pig rat prolactin antiserum (1:1.500). Then, the
slides were incubated for 1 h with aDIG (1:10) and a rhodamine-
conjugated anti-guinea pig secondary antibody (1:200). The
percentage of total apoptotic cells was calculated as (TUNEL-
positive cells/total anterior pituitary cells)6100. The percentage
of apoptotic lactotropes was calculated as (TUNEL-positive
prolactin-immunoreactive cells/prolactin-immunoreactive cells)
6100. The percentage of lactotropes determined by immunoflu-
orescence was between 25–40% of total anterior pituitary cells.
Western Blot
Total proteins were extracted from cultured cells in lysis buffer
containing protease inhibitor cocktail and phosphatase inhibitors
(10 mM NaF, 2 mM Na-orthovanadate, 80 mM b-glycerol
phosphate). The protein concentration of each sample was
determined by Bradford protein assay (BioRad Laboratories,
CA, USA). Twenty mg of total proteins were size-fractionated in
12% SDS-polyacrylamide gel and then electrotransferred to
polyvinyl difluoride (PVDF) membranes. Blots were blocked for
2 h in 5% nonfat dry milk-TBS-0.1% Tween 20 at room
temperature and incubated overnight with the appropriate
primary antibody in the same buffer at 4uC. The primary
antibodies used were: anti-p38 MAPK (1:1000) and anti-phospho-
p38 MAPK (1:2000). Then, membranes were incubated for 1 h at
room temperature with the corresponding peroxidase conjugated
secondary antibody. Immunoreactivity was detected by enhanced
chemiluminescence. Membranes were exposed to X-ray films and
developed using an X-Ray developer.
Statistical Analysis
Each experiment was performed at least twice. The percentage
of apoptotic cells determined by flow cytometry was expressed as
mean 6 SE and evaluated by two-way ANOVA followed by
Tuckey’s test. The optic density measured by ELISA was
expressed as mean 6 SE and analyzed by one-way ANOVA
followed by Dunnett’s test. The number of apoptotic cells
identified by TUNEL was determined in duplicate slides from
independent experiments. Results were expressed as the percent-
age 695% confidence interval (CI) of apoptotic cells of the total
number of cells counted in each specific condition. Differences
between proportions were analyzed by x2 test [2]. Differences
were considered significant if p,0.05.
Results
Effect of CAB on anterior pituitary cell apoptosis
To confirm the permissive action of E2 on the apoptotic action
of D2R activation in an in vivo model, apoptosis in the anterior
pituitary gland was evaluated in OVX and E2-treated rats injected
with CAB (determined by FICT Annexin-V staining). As
previously described [24], E2 treatment per se increased apoptosis
of anterior pituitary cells. Whereas CAB did not modify the
percentage of anterior pituitary apoptotic cells from OVX rats,
this D2R agonist induced apoptosis in the pituitary from E2-
treated rats (Fig. 1).
Effect of DA on the apoptosis of lactotropes expressing
D2L or D2S receptor isoforms
To study the role of D2R isoforms in the apoptosis of
lactotropes induced by DA, we evaluated the proapoptotic action
of this catecholamine on PR1 cells expressing either D2L or D2S.
Considering that DA-induced apoptosis of lactotropes is E2-
dependent [2], PR1 cells were incubated either in the presence or
absence of E2 (1 nM). DA did not modify the apoptosis
(determined by an ELISA assay) in PR1-V and PR1-D2L cells
incubated either in the absence or presence of E2 (Fig. 2A and B).
Whereas this catecholamine did not modify the apoptosis of PR1-
D2S cells incubated in the absence of E2 (Fig. 2A), DA induced
apoptosis of these cells when they were cultured with E2 (Fig. 2B).
We also analyzed the apoptotic action of DA in PR1 cells by
TUNEL assay. DA did not modify the percentage of TUNEL-
positive PR1-V and PR1-D2L cells incubated in the absence or
presence of E2 (data not shown). However, DA increased the
percentage of TUNEL-positive PR1-D2S cells only when these
cells were incubated with E2 (Fig. 3).
Involvement of p38 MAPK on DA-induced apoptosis
To investigate whether p38 MAPK is involved in the apoptosis
of anterior pituitary cells induced by D2R activation, anterior
pituitary cells from OVX rats cultured with E2, were incubated
with DA or CAB in the presence of SB203580, a p38 MAPK
Figure 1. CAB induces apoptosis of anterior pituitary cells in an
E2-dependent manner. OVX and E2 treated rats were injected with
CAB (1 mg/kg, ip) or vehicle (CONTROL) and euthanized 16 h later.
Anterior pituitary cells were dispersed and apoptosis was detected by
Annexin-V and flow cytometry. Each column represents the mean 6 SE
of the percentage of apoptotic cells (n = 8 rats/group). Data were
analyzed by two-way ANOVA, followed by Tuckey’s test. *p,0.05 vs.
respective control without CAB, ‘p,0.05 vs respective control without
E2.
doi:10.1371/journal.pone.0018097.g001
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inhibitor. SB203580 blocked the apoptotic effect of either DA or
CAB in anterior pituitary cells and lactotropes from primary
cultures (Fig. 4). Also, in PR1-D2S cells cultured with E2, the
apoptotic effect of DA was reverted by SB203580 (Fig. 5A). In
addition, we determined the effect of DA on p38 phosphorylation
in PR1 cells by western blot. DA did not modify p38
phosphorylation in PR1-V and PR1-D2L cells incubated either
in the absence or presence of E2 (data not shown). However, DA
induced p38 MAPK phosphorylation in PR1-D2S cells, an effect
that E2 seems to enhance (Fig. 5B).
Discussion
DA is the main inhibitor of lactotrope function and its
interaction with D2R not only inhibits PRL secretion, PRL gene
expression and lactotrope proliferation [1], but also induces
apoptosis of these cells [2]. D2R knock-out (KO) mice and mice
lacking the ability to synthesize DA show pituitary hyperplasia and
hyperprolactinemia [25–27]. Two isoforms of D2R are synthe-
sized by alternative splicing, D2S and D2L [1]. However, no
specific ligands exist allowing to discriminate D2S from D2L
actions. Therefore, KO animal models for D2L (D2L2/2)
[28,29] or animals with D2R isoforms overexpression [30] have
been developed. Also, cell lines expressing D2L or D2S isoforms
have been generated [20,23,31]. In GH3, a somatolactotrope cell
line lacking D2R, D2L and D2S were described to mediate
dopaminergic repression of PRL gen promoter when cells are
transfected with these isoforms [32]. However, whereas D2R2/2
female mice are hyperprolactinemic [26,27], D2L2/2 female
mice exhibit normal serum PRL levels [29]. Since D2L2/2 mice
express D2S, it has been suggested that D2S can substitute the
function of D2L in the control of PRL secretion [29]. However, it
Figure 2. DA increases apoptosis in PR1-D2S cells incubated in the presence of E2. PR1-V, PR1-D2L or PR1-D2S cells were cultured with
DMEM-F12-SS in the absence (A) or presence of E2 (1 nM, B) for 48 h. Then the cells were incubated with DA (1 mM-100 mM) in the presence or
absence of E2 for 4 h and apoptosis was detected by ELISA. Each column represents the mean 6 SE expressed of OD as the percentage of control
without DA (n = 5 wells/group). Data were analyzed by ANOVA followed by Dunnett’s test. * p,0.05 vs control without DA.
doi:10.1371/journal.pone.0018097.g002
Figure 3. DA increases the percentage of apoptotic PR1-D2S
cells incubated in the presence of E2. PR1-D2S cells were cultured
with DMEM-F12-SS in the absence (VEH) or presence of E2 (1 nM) for
48 h. Then the cells were incubated with DA (1 mM) with or without E2
for 4 h. Each column represents the percentage of TUNEL-positive cells
6 CI (.2,000 cells/group). Data from at least two separate experiments
were analyzed by x2. ** p,0.01 vs respective control without DA.
‘‘ p,0.01 vs respective control without E2.
doi:10.1371/journal.pone.0018097.g003
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is possible that only the D2S isoform is involved in the inhibition of
PRL release induced by DA. In fact, Iaccarino et al. demonstrated
that mice overexpressing D2S receptor show a reduction in
pituitary size, lactotrope number, PRL mRNA expression and
serum PRL levels compared to WT mice and D2L overexpressing
mice [30]. Also, DA was reported to exert an antiproliferative
action in PR1 cells expressing D2S receptor but not in PR1 cells
expressing the D2L isoform [23]. Both isoforms are expressed in
the anterior pituitary gland [1]. Even though the predominant one
is D2L [7–9], we show that DA induces apoptosis of PR1-D2S
cells, whereas D2L activation does not seem to be implicated in
DA proapoptotic action. It has been described that D2L receptor
is mainly localized in the perinuclear region around the Golgi
apparatus, whereas the short isoform is principally restricted to
the plasma membrane and is therefore more accessible to DA
agonists [31]. These observations suggest that DA effects on
lactotropes, such as reduction of PRL secretion, inhibition of
proliferation and induction of apoptosis, are mediated by the D2S
receptor isoform.
Since p38 MAPK has been implicated in DA-induced apoptosis
in neurons [19] and GH3 cells [20], we investigated involvement
of this kinase in the apoptosis of lactotropes. DA- or CAB-induced
apoptosis was reverted by a p38 MAPK inhibitor in anterior
pituitary cells from primary cultures and in PR1-D2S cells,
indicating that p38 MAPK is involved in the apoptosis of
lactotropes induced by D2R activation. It has been reported that
p38 and ERK are involved in DA-induced death in GH3 cells
expressing D2Rs [20] and that ERK participates in the inhibition
of cell proliferation in mice overexpressing D2S receptors [30].
Although p38 MAPK is involved in apoptosis of anterior pituitary
cells, we cannot rule out the participation of other signaling
pathways. We observed that DA phosphorylates p38 only in PR1-
D2S cells. DA was shown to signal by different intracellular
pathways in CHO cells transfected with D2L or D2S [33]. In
addition, in GH4 pituitary cell line, D2S activation inhibits the
phosphorylation of ERK induced by TRH whereas D2L
activation failed to induce this action [34]. These data and our
observations support the hypothesis that D2S and D2L receptor
are functionally distinct in terms of coupling to MAPK pathways.
The first choice of treatment for prolactinomas are DA receptor
agonists, being CAB the most effective one which inhibits PRL
secretion and reduces tumor size [10,35]. This drug suppresses
PRL release in in vitro and in vivo rodent models [11,12], and
decreases cell viability in non-functioning human pituitary
adenomas [36]. We previously reported that CAB induces
apoptosis of lactotropes only when cells are cultured in the
presence of E2 [2]. In this study, we show that administration of
CAB to OVX rats increases apoptosis in the anterior pituitary
gland only in E2-treated rats. These observations suggest that
CAB’s effect in reducing prolactinoma size involves induction of
Figure 4. A p38 MAPK inhibitor blocks the apoptosis of anterior pituitary cells induced by D2R activation. Anterior pituitary cells were
cultured with E2 (1 nM) for 48 h. Then the cells were preincubated with SB203580 (1 mM), a p38 MAPK inhibitor, for 30 min and then incubated with
DA (1 mM, A and B) or CAB (1 mM, C and D) in the presence or absence of SB203580 for 4 h. Each column represents the percentage of TUNEL-positive
cells 6 CI (.2,000 cells/group, A, C) or the percentage of TUNEL positive lactotropes 6 CI (.500 cells/group B, D). Data from at least two separate
experiments were analyzed by x2. ** p,0.01 vs respective control without DA or CAB. ‘ p,0.05 vs respective control without SB203589.
doi:10.1371/journal.pone.0018097.g004
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lactotrope apoptosis, and confirm that D2R activation induces
apoptosis of anterior pituitary cells in an estrogen-dependent
manner. We cannot discard that CAB induces apoptosis of non
lactotrope cells. D2R is found in more than 75% of anterior
pituitary cells, suggesting that non lactotrope cells express this
receptor [37]. In fact, we reported that D2R activation by DA
induces apoptosis of PRL- and non PRL-immunoreactive anterior
pituitary cells [2].
E2 increases the expression of D2L mRNA in anterior pituitary
cells [7–9]; however, we observed that D2S is the isoform
involved in DA proapoptotic action. Therefore, our results
suggest that E2 sensitizes anterior pituitary cells to DA by other
mechanisms not involving D2R isoforms expression modulation.
In fact, D2S expression in PR1 cells is not sufficient to induce
apoptosis by DA, which requires E2-permissive action to produce
this effect. This sensitization induced by E2 could be associated
with changes in transduction pathways triggered by D2S
activation. Whereas DA-induced apoptosis was prevented by a
p38 MAPK inhibitor, D2S activation induced p38 phosphoryla-
tion, not only in the presence but also in the absence of E2.
Considering that apoptosis induced by D2S receptor activation
was only observed when cells were cultured in the presence of E2,
the phosphorylation of p38 MAPK induced by DA seems to be a
necessary but not a sufficient event to induce apoptosis of
lactotropes. Our results show that E2 increases phosphorylation
of p38 MAPK and suggest that this steroid enhances kinase
activation induced by DA. p38 MAPK phosphorylation leads
to activation of caspase 8 and 9, and proapoptotic proteins of
the Bcl-2 family to trigger apoptosis via mitochondrial and
extramitocondrial pathways [38]. We previously reported that E2
increases the ratio between proapoptotic and antiapoptotic
proteins of the Bcl-2 family in the anterior pituitary [39]. In
addition, since E2 increases p53 expression in this gland [40] and
p53 was reported to be a target of p38 MAPK [41], the
sensitization induced by E2 on anterior pituitary cells could
involve an increment in p38 MAPK phosphorylation leading to
p53 activation.
Prolactinomas are the most frequent pituitary tumors and
medical therapy with D2R agonists is highly effective in most
cases. However, some patients do not respond to pharmacological
treatment [42]. D2R expression reduction and alterations in the
intracellular pathways triggered by D2R activation have been
associated with D2R agonist-resistance [10,35]. In addition,
differential expression of D2R isoforms may also be implicated
in the resistance to these drugs. In fact, it has been reported that
resistant prolactinomas have less expression of D2S mRNA than
the responsive ones [14,15]. It is also possible to speculate that low
levels of estrogens in patients with hypogonadism induced by
hyperprolactinemia may contribute to the development of
pituitary adenomas and resistance to D2R agonist treatment. It
would be interesting to study the relationship between circulating
levels of estrogens in patients with prolactinomas and their
response to DA agonist treatment.
Our study shows that the apoptosis of lactotropes induced by
DA is mediated by D2S and is an estrogen-dependent process,
involving p38 MAPK activation. These observations suggest that a
decrease in D2S expression may participate in D2R agonist
resistant prolactinomas.
Figure 5. p38 MAPK is involved in DA-induced apoptosis of PR1-D2S cells. A: PR1-D2S cells were cultured with E2 (1 nM) for 48 h. Then the
cells were preincubated with SB203580 (1 mM), a p38 MAPK inhibitor, for 30 min and then incubated with DA (1 mM) in the presence or absence of
SB203580 for 4 h. Each column represents the percentage of TUNEL-positive cells 6 CI (.2,000 cells/group). Data from at least two separate
experiments were analyzed by x2. ** p,0.01 vs respective control without DA. ‘‘ p,0.01 vs respective control without SB203580. B: PR1-D2S cells
were cultured with or without E2 (1 nM) for 48 h. Then the cells were incubated with DA (1 mM) in the presence of E2 or VEH for 15 min, 30 min or
4 h. Proteins were extracted and p38 MAPK and phospho-p38 MAPK were detected by western blot.
doi:10.1371/journal.pone.0018097.g005
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